NYSE:BMY - Bristol-Myers Squibb Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$49.60 +0.47 (+0.96 %)
(As of 01/18/2019 07:32 AM ET)
Previous Close$49.13
Today's Range$48.4708 - $49.8850
52-Week Range$44.30 - $70.05
Volume21.20 million shs
Average Volume17.73 million shs
Market Capitalization$80.19 billion
P/E Ratio16.48
Dividend Yield3.34%
Beta0.98
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; Tsinghua University; Sirenas; Vedanta Biosciences, Inc.; and Boston Medical Center. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP11012210
Phone212-546-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.78 billion
Cash Flow$3.5530 per share
Book Value$7.24 per share

Profitability

Net Income$1.01 billion

Miscellaneous

Employees23,700
Outstanding Shares1,632,200,000
Market Cap$80.19 billion
OptionableOptionable

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 6th. Stockholders of record on Friday, January 4th will be given a dividend of $0.41 per share on Friday, February 1st. This represents a $1.64 annualized dividend and a dividend yield of 3.31%. The ex-dividend date is Thursday, January 3rd. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.40. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) issued its earnings results on Thursday, October, 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.91 by $0.18. The biopharmaceutical company had revenue of $5.69 billion for the quarter, compared to analysts' expectations of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Bristol-Myers Squibb.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, January 24th at 10:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8004584121.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2019 earnings guidance on Thursday, January, 3rd. The company provided earnings per share guidance of $4.10-4.20 for the period.

What price target have analysts set for BMY?

20 Wall Street analysts have issued 12 month price objectives for Bristol-Myers Squibb's stock. Their forecasts range from $47.00 to $76.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $61.0894 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price. View Analyst Price Targets for Bristol-Myers Squibb.

What is the consensus analysts' recommendation for Bristol-Myers Squibb?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 12 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bristol-Myers Squibb.

Has Bristol-Myers Squibb been receiving favorable news coverage?

Media headlines about BMY stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.

Who are some of Bristol-Myers Squibb's key competitors?

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 54)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
  • Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 58)
  • Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 58)
  • Mr. Joseph C. Caldarella, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 63)

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.09%), Douglas Lane & Associates LLC (0.08%), Hexavest Inc. (0.06%), RNC Capital Management LLC (0.05%), DNB Asset Management AS (0.04%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.

Which institutional investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Gulf International Bank UK Ltd, Patten & Patten Inc. TN, RNC Capital Management LLC, Howard Capital Management, First American Trust FSB, 6 Meridian and Pennsylvania Trust Co. View Insider Buying and Selling for Bristol-Myers Squibb.

Which institutional investors are buying Bristol-Myers Squibb stock?

BMY stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Atalanta Sosnoff Capital LLC, DNB Asset Management AS, Centre Asset Management LLC, Stock Yards Bank & Trust Co., Town & Country Bank & Trust CO dba First Bankers Trust CO, Douglas Lane & Associates LLC and Meeder Asset Management Inc.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $49.60.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $80.19 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is http://www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29th Street 14 Floor, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  881 (Vote Outperform)
Underperform Votes:  804 (Vote Underperform)
Total Votes:  1,685
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel